Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

NCT04634435 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

COMBINATION_PRODUCT: BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2

Sponsor

Biohaven Pharmaceuticals, Inc.

Collaborators

[object Object]